Literature DB >> 32643982

Ocular Complications of Checkpoint Inhibitors and Immunotherapeutic Agents: A Case Series.

Ruby A Parikh1, Benjamin C Chaon1, Meghan K Berkenstock1.   

Abstract

Background: Ophthalmologists have a role in assessing immune-related adverse events (IRAE) in oncology patients on immunotherapy. We assessed the utility of a hospital-wide toxicity team in referring patients with new ocular symptoms for examination. We also identified new immunotherapy agents causing ocular side-effects.Design: A cohort study of eight consecutive patients on immunotherapy, who developed ocular IRAE from November 1, 2017 to June 30, 2019. All were seen at the Ocular Immunology Division of the Wilmer Eye Institute and referred by the Johns Hopkins Toxicity Team.
Results: All eight patients on had IRAEs; were treated with corticosteroid drops or observation with clinical resolution. Two new agents, epocadostat and daratumumab, were associated with the development of uveitis.
Conclusion: Ophthalmologists play an important role in a hospital-wide toxicity team and need to include IRAEs in their differential diagnosis. Given new drug development, ophthalmologists may be the first to identify IRAEs.

Entities:  

Keywords:  Uveitis; drug toxicity; immunotherapy; multidisciplinary coordination of care; ocular adverse events

Mesh:

Substances:

Year:  2020        PMID: 32643982     DOI: 10.1080/09273948.2020.1766082

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  7 in total

Review 1.  Ocular Toxicity of Targeted Anticancer Agents.

Authors:  Blake H Fortes; Prashant D Tailor; Lauren A Dalvin
Journal:  Drugs       Date:  2021-03-31       Impact factor: 9.546

2.  Ocular adverse events associated with immune checkpoint inhibitors: a novel multidisciplinary management algorithm.

Authors:  Orthi Shahzad; Nicola Thompson; Gerry Clare; Sarah Welsh; Erika Damato; Philippa Corrie
Journal:  Ther Adv Med Oncol       Date:  2021-02-12       Impact factor: 8.168

3.  Immune Checkpoint Inhibitor Treatment and Ophthalmologist Consultations in Patients with Malignant Melanoma or Lung Cancer-A Nationwide Cohort Study.

Authors:  Maria D'Souza; Mette Bagger; Mark Alberti; Morten Malmborg; Morten Schou; Christian Torp-Pedersen; Gunnar Gislason; Inge Marie Svane; Jens Folke Kiilgaard
Journal:  Cancers (Basel)       Date:  2021-12-23       Impact factor: 6.639

Review 4.  The Cellular Composition of the Uveal Immune Environment.

Authors:  Ian R Reekie; Srilakshmi Sharma; Andrew Foers; Jonathan Sherlock; Mark C Coles; Andrew D Dick; Alastair K Denniston; Christopher D Buckley
Journal:  Front Med (Lausanne)       Date:  2021-10-29

5.  Atezolizumab-induced bilateral anterior uveitis: A case report.

Authors:  Tsuyoshi Mito; Shun Takeda; Nozomu Motono; Hiroshi Sasaki
Journal:  Am J Ophthalmol Case Rep       Date:  2021-09-14

Review 6.  Various clinical presentations of uveitis associated with durvalumab treatment.

Authors:  Nika Vrabic; Ana Fakin; Polona Jaki Mekjavic; Urska Janzic; Martina Vrankar; Natasa Vidovic Valentincic
Journal:  Radiol Oncol       Date:  2022-04-12       Impact factor: 4.214

7.  Ocular Inflammation Induced by Immune Checkpoint Inhibitors.

Authors:  Florence Chaudot; Pascal Sève; Antoine Rousseau; Alexandre Thibault Jacques Maria; Pierre Fournie; Pierre Lozach; Jeremy Keraen; Marion Servant; Romain Muller; Baptiste Gramont; Sara Touhami; Habeeb Mahmoud; Pierre-Antoine Quintart; Stéphane Dalle; Olivier Lambotte; Laurent Kodjikian; Yvan Jamilloux
Journal:  J Clin Med       Date:  2022-08-25       Impact factor: 4.964

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.